摘要
目的观察负荷剂量伊班膦酸钠二线治疗乳腺癌转移性骨痛患者的有效性及安全性。方法前瞻性观察2010年1月至2014年8月,我科收治的130例晚期乳腺癌骨转移并伴有中-重度骨痛的患者,二线使用负荷剂量伊班膦酸治疗前后的疼痛评分、止痛药物的剂量及生活质量(karnofsky performance status,KPS)评分等变化情况,并记录血生化指标及其它安全性。结果 126例纳入最终分析。患者治疗后第1、2、3周疼痛评分较治疗前均明显降低(均P<0.01);同时治疗后第1、2、3周的阿片类药物(羟考酮)的用量均较治疗前明显减少(均P<0.01);治疗后第1、2、3周的KPS评分较治疗前均明显升高(均P<0.01)。其中89例疼痛得到有效缓解,缓解率70.6%。中度疼痛患者镇痛显效时间短于重度疼痛患者(P<0.05)。治疗不良反应少,未见明显的肝肾毒性反应。结论负荷剂量的伊班膦酸钠二线治疗乳腺癌转移性骨痛起效快、疗效好,不良反应轻,可提高患者生活质量,减少镇痛药物的用量。
Objective To evaluate the effectiveness and safety of second-line treatment of bone pain in the patients of metastatic breast cancer with a loading dose of ibandronate.Methods A prospective observational study was conducted in 130 patients with advanced and metastatic breast cancer combined by moderate-severe bone pain who were admitted and received second-line treatment with a loading dose of ibandronate from January 2010 to April 2014. The pain score, consumption of analgesic drug, Karnofsky performance status （ KPS ） score were recorded before and after the treatment in all the patients. Meanwhile, their blood biochemical indices and safety were documented.Results In the ifnal analysis, 126 patients were included. When compared with the scores before the treatment, the pain scores were signiifcantly reduced （P〈0.01 ） and the KPS scores were signiifcantly increased （P〈0.01 ） at 1, 2 and 3 weeks after the treatment. And meanwhile, the administration dose of analgesic drug （ oxycodone ） was obviously reduced at 1, 2 and 3 weeks after the treatment when compared with the dose before the treatment （P〈0.01 ）. Bone pain was effectively alleviated in 89 patients, and the remission rate was 70.6%. The effective analgesic time in the patients with moderate pain was signiifcantly shorter than that in the patients with severe pain （P〈0.05 ）. Besides, few adverse drug reactions and no obvious liver or renal toxicity were observed among the 126 patients.Conclusions The second-line treatment of bone pain with a loading dose of ibandronate in the patients with metastatic breast cancer is effective and well tolerated. The patients’ quality of life will be improved and the amount of analgesic drugs will be reduced.
出处
《中国骨与关节杂志》
CAS
2015年第4期302-305,共4页
Chinese Journal of Bone and Joint
关键词
癌
乳腺乳腺
人
乳腺肿瘤
肿瘤转移
伊班膦酸钠
Carcinoma
Mammary glands,human
Breast neoplasms
Neoplasm metastasis
Ibandronate
